


online *Services for Readers*



<http://www.ada.diabetes.org>

The American Diabetes Association has introduced new World Wide Web services for members and subscribers. The publications home page offers:

- Tables of contents and a searchable database of abstracts from the current and back issues of *Diabetes* and *Diabetes Care* and selected articles from *Diabetes Care*.
- Tables of contents and selected articles from *Diabetes Spectrum* and *Diabetes Forecast*.
- Full text of *Clinical Practice Recommendations 1997*, the Association's annual compendium of position statements.
- Information about and online ordering for books and other resources for health professionals and people with diabetes.
- Information about and online ordering for membership in the Professional Section of the American Diabetes Association.
- Links to other diabetes sites on the Internet, including newsgroups and World Wide Web pages.
- A professional-to-professional forum for discussing articles in Association publications and other issues in diabetes research and treatment. (This service is available only to Professional Section members of the American Diabetes Association.)



DUALITY OF INTEREST DISCLOSURE FORM FOR AUTHORS OF ARTICLES IN AMERICAN DIABETES ASSOCIATION PUBLICATIONS

I have read the American Diabetes Association's Duality of Interest Policy Statement (found in the January and July issues of *Diabetes* and *Diabetes Care*), and I am indicating below that I have or have not had in the previous 12 months a relevant duality of interest with a company whose products or services are *directly* related to the subject matter of my manuscript. A relevant duality of interest includes employment, membership on the board of directors or any fiduciary relationship, membership on a scientific advisory panel or other standing scientific/medical committee, ownership of stock, receipt of honoraria or consulting fees, or receipt of financial support or grants for research. Company is defined as a for-profit concern engaged in the development, manufacture, or sale of pharmaceutical or biomedical devices or supplies.

Each author must sign this form. (The form may be photocopied if needed.)

	Check each area that applies					
	Yes	No	Yes	No	Yes	No
Employment	_____	_____	_____	_____	_____	_____
Membership on an advisory panel, standing committee, or board of directors	_____	_____	_____	_____	_____	_____
Stock shareholder	_____	_____	_____	_____	_____	_____
Honoraria or consulting fees	_____	_____	_____	_____	_____	_____
Grant/research support	_____	_____	_____	_____	_____	_____
Author (please type or print)	_____		_____		_____	
Signature	_____		_____		_____	
Date	_____		_____		_____	

For each item checked "yes," please list on a separate sheet of paper the third-party organization with whom you have relevant affiliations or interests. Please provide sufficient information to enable the American Diabetes Association to make an informed decision. Include 1) the nature of the activity that is a relevant duality, 2) the type of financial arrangement, if any, between you and the third party, and 3) a description of the business or purpose of the third party. Please see the following sample disclosures.

SAMPLE DISCLOSURES FOR AUTHORS

Employment

I am employed by Exacta Pharmaceutical Company (6250 Longwood Avenue, Any City, Missouri). My employer manufactures and markets pharmaceuticals related to the treatment of diabetes and its complications.

Board Membership

I am on the board of directors of the Exacta Pharmaceutical Company, a manufacturer of pharmaceuticals related to the treatment of diabetes.

Stock Shareholder

I, or my immediate family, hold stock in the following companies that make products related to the treatment or management of diabetes and its complications:

XYZ Corporation
LMN Corporation

Honoraria or Consulting Fees

I have received honoraria for speaking engagements from the following:

XYZ Corporation
LMN Corporation

I am a paid consultant of the XYZ Corporation.

Grants


The XYZ Corporation is providing funds to my laboratory in order to conduct studies on a new drug to treat diabetic neuropathy.

By answering "yes" in any category, the Association will disclose the relevant duality of interest. The Association will make the disclosure by placing an asterisk by the author's name, and in a footnote describe the nature of the duality of interest, e.g., stock ownership or grant support, and the third party involved.

This form must be returned with your submission. Make additional copies as needed for all authors. Failure to complete the disclosure may delay or prevent publication of your article.

Now that they have diabetes, they know how crucial diet and exercise are.

Since it's
hard to change
lifestyle,
their first
diabetic agent
should be
easy.



Choose it for **control**.

Choose it for **convenience**.

Choose it for improved patient
quality of life.¹

When diet alone fails in NIDDM*...

*Non-insulin-dependent diabetes mellitus.
† Gastrointestinal therapeutic system.

**As with all sulfonylureas,
hypoglycemia may occur.**

*Please see brief summary of prescribing
information on adjacent page.*

Reference: 1. Testa MA, Simonson DC. Beneficial
effects of glipizide GITS on glycemic control, quality
of life and symptom distress in NIDDM.
Diabetes. May 1996;45(suppl 2):123A. Abstract 450.



ONCE DAILY
Glucotrol XL[®]
(glipizide) *extended release*
Tablets 5 mg and 10 mg GITS[†]